Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

Not Recruiting

Trial ID: NCT01926990

Purpose

This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Official Title

Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

Stanford Investigator(s)

Aya Kamaya, MD
Aya Kamaya, MD

Professor of Radiology (Body Imaging)

Alice C. Fan
Alice C. Fan

Associate Professor of Medicine (Oncology) and, by courtesy, of Urology

Benjamin I. Chung
Benjamin I. Chung

Associate Professor of Urology

James D. Brooks
James D. Brooks

Keith and Jan Hurlbut Professor

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Dominik Fleischmann
Dominik Fleischmann

Professor of Radiology (Cardiovascular Imaging)

Eligibility


Inclusion Criteria:

   - Suspected or biopsy-proven renal cell carcinoma

   - Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib,
   nivolumab alone or in combination with an investigational agent

   - Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

   - Serum creatinine greater than or equal to 1.7 mg/dL

   - Severe allergy to contrast agent

   - Any contraindication for undergoing a CT scan

   - Pregnancy or unwillingness to use preventative measures if a woman of child-bearing
   potential

Intervention(s):

device: perfusion computed tomography

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Yoriko Imae
650-498-5186

New Trial Alerts